Biotech stocks offer some of the most explosive opportunities.
That is, if you spot the right ones.
For example, some of the hottest ideas can be found in weight loss drugs, cancer treatments known as ADCs (antibody-drug conjugates), and in gene-editing.
Look at CRISPR Therapeutics (CRSP), for example. Not long ago, it received US FDA approval for its gene-editing therapy for sickle cell disease and transfusion-dependent beta-thalassemia, a genetic disorder that prevents the production of hemoglobin in the blood and requires regular blood transfusions.
With that news, we watched CRISPR jump from about $40 to $70.
Or, look at Eli Lilly (LLY). Thanks to strong demand for obesity medication, the stock popped from about $580 to $760, and it’s still moving higher.
We even just saw it happen with Viking Therapeutics (VKTX), which gapped from about $35 to $89.35 after seeing positive study results for its obesity treatment.
Of course, there are many more. But you get the point.
What makes biotech even hotter is that major drug companies are on a shopping spree.
Over the next few years, drug giants could lose billions to patent expirations. According to EY analysts, the top 20 giants could lose about $180 billion in sales by the end of the decade. To stop some of the potential bloodshed, companies are building up their pipelines, bring in fresh new drugs with multi-billion-dollar potential. For example, most recently, Johnson & Johnson said it would acquire Ambrx Biopharma for $2 billion. Pfizer acquired Seagen for $43 billion.
Again, we could go on, but you get the point.
While you can always buy individual biotech names in hopes they explode, you can also buy exchange-traded funds (ETFs) that have been running, too.
| Company: SPDR S&P Biotech ETF (XBI) One of the best ways to diversify at less cost is with a biotech ETF, such as the SPDR S&P Biotech ETF (XBI). With an expense ratio of 0.35%, the ETF offers exposure to the S&P Biotechnology Select Industry Index. Since November, the ETF ran from about $65 to a recent high of $101. While it could pullback near term, it could see higher highs long term. |
Learn how Jack Harris turned his $2k into $83k
He began as a retail trader who made nearly every mistake in options trading and lost a bunch of money. But everything changed when he uncovered a secret trading tool called “dark pool tracker.” Jack wrote down everything in a new e-book that described his method (including a proof of his unusual result), which quickly became an international best-seller.
He’s allowing Behind the Markets readers an exclusive opportunity to gain access to this book for free, but that won’t last long. Grab your copy today!
Click here to claim your FREE copy!
| Company: ProShares Ultra NASDAQ Biotechnology (BIB) With an expense ratio of 0.95%, the BIB ETF seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index. Since November, the BIB ETF ran from about $42 to a high of $62. Here, too, it could see a near-term pullback, but higher highs over the long haul. |
Biggest Investors in the World LOADING UP on This AI Stock
It’s a small cap that trades for less than $10… Yet the biggest investors in the world own millions of shares.
Why? Because their AI just did something no company has ever done before.
Details here.
| Company: iShares Biotechnology ETF (IBB) With an expense ratio of 0.44%, the IBB ETF tracks the investment results of an index composed of U.S.-listed equities in the biotechnology sector. The IBB ETF has been just as explosive, running from about $112.50 to a recent high of $139.83. Again, as with XBI and BIB, it could pull back near-term, but run to higher highs long-term. |
